Bionexus Gene Lab Corp. Revenue 2018–2025
Bionexus Gene Lab Corp. annual/quarterly revenue history and growth rate from 2018 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Bionexus Gene Lab Corp. revenue for the quarter ending March 31, 2026 was 22842, a 98.93% decrease year-over-year.
- Bionexus Gene Lab Corp. revenue for the twelve months ending March 31, 2026 was 7.0 M, a 27.01% decrease year-over-year.
- Bionexus Gene Lab Corp. annual revenue for 2025 was 7.4 M, a 21.93% decrease from 2024.
- Bionexus Gene Lab Corp. annual revenue for 2024 was 9.5 M, a 2.66% decrease from 2023.
- Bionexus Gene Lab Corp. annual revenue for 2023 was 9.8 M, a 10.60% decrease from 2022.
- Bionexus Gene Lab Corp. annual revenue for 2022 was 10.9 M.
Bionexus Gene Lab Corp. (BGLC) — Frequently Asked Questions
Bionexus Gene Lab Corp. (BGLC) is a publicly traded US company. It has a market capitalization of $5M. In fiscal 2025 it reported revenue of $7M and net income of -$3M. Explore BGLC's stock price, financial statements, earnings history, margins and key ratios below.
What is Bionexus Gene Lab Corp.'s market cap?
Bionexus Gene Lab Corp. (BGLC) has a market capitalization of $5M.
What is the BGLC stock price?
BGLC trades at $2.11 (+7.11% on the day).
How much revenue does Bionexus Gene Lab Corp. make?
Bionexus Gene Lab Corp. reported revenue of $7M in fiscal 2025.
Is BGLC profitable?
In fiscal 2025, Bionexus Gene Lab Corp. reported net income of -$3M.